

Special Issue

Alzheimer's Disease: Pathogenesis, Diagnostics and Novel Treatment Options

Message from the Guest Editors

For this Special Issue, we invite manuscripts focusing on Alzheimer's disease (AD) on a variety of topics, ranging from fundamental pathophysiological mechanisms studies to clinical proof of concept and proof of mechanism studies. We encourage submissions focusing on the basic science on AD pathogenesis, including but not limited to the roles of amyloid and tau pathologies, neuroinflammation, mitochondrial dysfunction, and synaptic dysfunction. Cutting-edge research on diagnostics is welcome, such as fluid biomarkers (e.g. novel CSF and blood tests) and neuroimaging modalities. Studies leveraging AI-based diagnostics and machine learning for early identification and prognostication of AD are particularly encouraged. On the therapeutic front, we seek reports on all innovative strategies, including preclinical pharmacology or clinical studies, empirical and mechanistic modeling, as well as meta-analyses on promising disease-modifying therapies encompassing all modalities (such as small molecules, antibodies, and gene therapy).

Guest Editors

Dr. Rui Zhong

Clinical Pharmacology and Pharmacometrics, Bristol Myers Squibb,
Lawrence Township, NJ 08648, USA

Prof. Dr. Ling Li

Department of Experimental and Clinical Pharmacology, University of
Minnesota, Minneapolis, MN 55455, USA

Deadline for manuscript submissions

30 April 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/255882

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).